Stock Talk
After the Test Position — What's Next?
Last week we talked about using smaller "test positions" to get a feel for stocks and gauge the market while preserving dry powder.
But after that, what's next?
Sometimes it may call for trading even small shares, trimming, holding, or even adding shares.
Even beyond keeping in mind fundamentals of growth and earnings prospects. What makes a particular company stand out? What could improve its prospects? And perhaps just as important, where will investor sentiment be heading?
Sometimes adding a few shares on dips makes sense. Other times, adding small tranches even on upticks as investors begin to catch on could be worth considering.
The idea isn't to predict every market turn.
So let's take another look at a few stocks on the Jones List, why they're there, and what might make them outperform, even if the market hasn't caught on yet.
Why Some Are on the Jones List
Gold Miner
KGC — Kinross Gold: A gold producer generating strong cash flow, returning money to shareholders through dividends and buybacks. While concerns about rising costs have corrected the share level from the high 30's down to the low 20's - looking at the earnings reports remain impressive, If KGC were a tech stock or a bitcoin miner - the market would likely be valuing over a $2 eps in the 60's and higher! Is KGC screaming Buy buy buy? Maybe "some" KGC with the way things are is a Jones way of looking at it.
Consumer Stocks — Dividends
KMB — Kimberly-Clark: One of those companies making things people need in good times and bad. With the addition of Kenvue, including brands like Tylenol and Neutrogena, KMB has become an even bigger consumer health business. And it pays a dividend while investors see how the combination works out.
MO — Altria: The tobacco business isn't going away tomorrow, and neither is the attraction of MO's substantial dividend. The company continues to generate cash while expanding into smoke-free products. Here, income is a big part of the attraction. Say what you may but MO has raised dividends consistently over the years and is at a 5.6% rate as of this note.
Semiconductors
NVTS — Navitas Semiconductor: The AI boom requires enormous amounts of electricity, and NVTS makes advanced power semiconductors using GaN and silicon carbide technology to help manage it more efficiently. Its partnership with GFS brings American manufacturing into the picture. Small company, powerful chips. See the earlier Jones report special edition. The one thing is it's gonna take a little time for earnings to grow positive. But when it starts - watch NVTS. Until then? Some is the word we use.
GFS — GlobalFoundries: A U.S.-based semiconductor manufacturer, previously owned by AMD and making its CPUs before AMD sold it off. Now a separate company, GFS still makes some peripheral chips for AMD, along with chips used in everything from refrigerators, RF devices and automobiles to more advanced applications. GFS is also moving into quantum-based chips, photonics and power chips, as pointed out in the Jones Report on NVTS. Domestic chip manufacturing, a global presence and AI infrastructure are a big part of the flair of GFS. America needs GFS as much as GFS needs America to thrive.
LRCX — Lam Research: The machines that help make the chips that make AI possible. Etching and deposition tools are the Lam specialty from this California based company - and they ALL need it. Lam is already generating impressive earnings, and the growing complexity of semiconductor manufacturing could keep demand strong for years. The question isn't whether Lam has a business. It's how much growth the market will price into the shares.
KLAC — KLA Corporation: Another critical player in the semiconductor equipment business, particularly inspection and process control. As chipmakers push technology to smaller dimensions and more complex designs, getting acceptable manufacturing yields becomes critical. That's where KLAC stands out.
Defense
VVX — V2X: A defense contractor that doesn't always get the attention of the big defense names. Yet with a backlog of $12.8 billion and improving earnings, there's plenty of business already on the books. These complicated U. S. fighters and transport military aircraft require a LOT of maintenance and support all around the globe. VVX has been a consistent and reliable partner with the U.S, and other friendly that depend proper aircraft upkeep. And VVX being where the action is has proven that they can help rapid prototype and collaborate to provide other defense solutions like The Tempest buggy we saw being deployed in the Youtube from Ukraine.
KTOS — Kratos Defense: Drones, hypersonics and advanced military systems are changing the battlefield. KTOS is involved in these technologies, and recent revenues and orders have been growing sharply. Her at the Jones report KTOS was originally highlighted in the teens. The stock rose to over $100 a share and has since faded to the 30's. The recent adjusted eps of 0.24 points to KTOS very possibly turning the corner. The drones are quite impressive as illustrated in a prior Jones report. KTOS is a valuable American asset for U.S. defense.
Speculative Biotech
XERS — Xeris Biopharma: With FDA-approved Recorlev for treating Cushing syndrome, XERS has turned profitable on a quarterly basis and raised projections to over $1 billion in total annual revenues by 2030. Recorlev itself could eventually approach a billion dollars annually. That's quite a development for a company that was little noticed by investors not long ago.
CMPS — Compass Pathways: Developing a psilocybin-based treatment for people suffering from treatment-resistant depression. Two successful Phase 3 trials and a completed FDA application bring CMPS closer to a possible new treatment in mental health. If approved, a large unmet medical need could become a substantial market.
HELP — Helus Pharma: Another company pursuing new approaches to depression and anxiety. Its lead treatment has shown promising earlier results, with important Phase 3 data expected before year-end. Here, clinical results could determine whether investors catch on or move on.
INO — Inovio Pharmaceuticals: After years of developing DNA-based medicine, INO finally gained accelerated FDA approval for VOCERYQ to reduce surgeries in patients with recurrent respiratory papillomatosis. Now comes the challenge of turning a scientific achievement into commercial success. The recent stock offering diluted shareholders but supplied badly needed cash.
ONCY — Oncolytics Biotech: Pelareorep has produced some interesting clinical results in cancer treatment, including two complete responses in an earlier anal cancer combination study. But here, the randomized REO 033 colorectal cancer trial and its approaching response data are what matter now. The market has heard the story and it was highlighted here. Let's see the clinical results.
Anthropic IPO Play
SKM — SK Telecom: A major Korean telecommunications company that made an early $100 million investment in Anthropic, the AI company behind Claude. With Anthropic preparing to go public at an enormous valuation, that early investment has become interesting indeed. This is why SKM is a watch stock, plain and simple reason.
Stay Watchful.